1. Volume 25, Issue 4, Pages 327-333 (December 2018)
Potential use of bitter melon (Momordica charantia) derived compounds as antidiabetics: In silico and in vivo studies 
Olusola Olalekan Elekofehinti, Esther Opeyemi Ariyo, Moses Orimoloye Akinjiyan, Olanrewaju Sam Olayeriju, Akeem Olalekan Lawal, Isaac Gbadura Adanlawo, Joao Batista Teixeira Rocha 
Pathophysiology 
Volume 25, Issue 4, Pages (December 2018)
DOI: /j.pathophys
Copyright © 2018 Elsevier B.V. Terms and Conditions

2. Fig. 1
Qualitative-PCR analysis of GLP-1 expression in M. charantia fed rats (n = 5) for 72 h. Snapshot represention of RT-PCR and chain reaction-agarose gel electrophoresis was carried on GLP-1 gene followed by desitometric analysis.
Pathophysiology  , DOI: ( /j.pathophys )
Copyright © 2018 Elsevier B.V. Terms and Conditions

3. Fig. 2
Qualitative-PCR analysis of DPP-4 expression in M. charantia fed rats (n = 5) for 72 h. Snapshot represention of RT-PCR and chain reaction-agarose gel electrophoresis was carried on DPP-4 gene followed by desitometric analysis.
Pathophysiology  , DOI: ( /j.pathophys )
Copyright © 2018 Elsevier B.V. Terms and Conditions

4. Fig. 3 Phytocompounds derived from M. charantia.
Pathophysiology  , DOI: ( /j.pathophys )
Copyright © 2018 Elsevier B.V. Terms and Conditions

5. Fig. 4
Binding pose of phytocompounds (sphere representation) derived from M. charantia into the active site of (a)DPP4, (b) GLP-1 and (c) TGR5.
Pathophysiology  , DOI: ( /j.pathophys )
Copyright © 2018 Elsevier B.V. Terms and Conditions